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Abstract  
AIM: This work was done to study the effect of both types of diabetes mellitus (DM) on myocardial 
contractility in rats. Also, we investigated the role of treatment of DM with insulin and rosiglitazone 
(used as treatment for type 1 and type 2 DM respectively) in improvement of myocardial 
dysfunction in diabetic rats. 
METHODS: The study included 50 male Wistar albino rats, divided into 5 groups: control (group I), 
streptozotocin induced type 1 DM (group II), fructose induced type 2 DM (group III), insulin treated 
type 1 diabetic rats (group IV) and rosiglitazone treated type 2 diabetic rats (group V). At the end of 
the study, retro-orbital blood samples were withdrawn and blood glucose, plasma triglyceride (TG), 
total cholesterol (TC) and thyroid hormones levels were measured. Rats were then anesthetized 
and their hearts were excised and connected to Langendorff apparatus to perform mechanical 
cardiac performance tests including heart rate (HR), left ventricular developed pressure (LVDP) and 
maximum rate of pressure rise (+dp/dt). 
RESULTS: Data of the study showed that relative to control group, there was significant increase in 
blood glucose, plasma TG and TC levels while, thyroid hormones and myocardial performance 
parameters showed significant decrease in both type 1 and type 2 diabetic rats. Treatment of type 1 
diabetic rats with insulin and type 2 with rosiglitazone resulted in significant decrease in blood 
glucose, plasma TG and TC levels associated with significant improvement in thyroid hormones 
and myocardial performance parameters. The results also showed that insulin treatment of type 1 
was more effective in ameliorating all parameters than treatment of type 2 by rosiglitazone. 
CONCLUSION: We concluded that the induction of both types of diabetes resulted in decreased 
myocardial performance parameters. The  treatment of type 1 and type 2 diabetes by insulin and 
oral rosiglitazone respectively improved to a great extent the altered metabolism and  mechanical 
myocardial parameters, with more improving effect of  insulin in type 1 than rosiglitazone in type 2 
DM.  
 
 
Introduction 
Diabetes mellitus is a metabolic disorder 
characterized by the presence of hyperglycemia due 
to defective insulin secretion, defective insulin action 
or both. Patients with diabetes have a higher risk of 
cardiovascular events accounting for substantial 
premature morbidity and mortality [1]. Many studies in 
humans reported the existence of a diabetic 
cardiomyopathy (DCM). The underlying mechanisms 
of this cardiomyopathy are still incompletely 
understood because of experimental limitations in 
humans. Rodent models of type 1 and type 2 diabetes 
mellitus (DM) share several traits with human DCM 
and have greatly advanced the understanding of the 
underlying pathology of DCM [2]. Contractile 
dysfunction was observed in perfused hearts from 
diabetic mice. There was evident increase in left 
ventricular end diastolic pressure and decreased left 
ventricular developing pressure, cardiac output and 
cardiac power [3]. Also, diabetes affects the thyroid 
hormones level and is thought to be associated with 
decreased serum levels of thyroid hormones {3,3′,5-
triiodo-L-thyronine (T3) and thyroxine (T4)}. Since 
insulin treatment improves both T3/T4 levels and β-
adrenoceptor-mediated responses, it points out a 
possible relationship between insulin and thyroid 
hormones [4]. More importantly, left ventricular 
hypertrophy and diastolic dysfunction without 
hypertension in type 2 diabetics may be associated 
with elevated insulin resistance. The use of 
troglitazone (TRO) which is known to increase insulin 
sensitivity and decrease insulin resistance has 
resulted in an improvement in diastolic function [5]. 
Recently, the protective role of thyroid hormones was 
described in streptozotocin induced diabetes [6]. It 
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was reported that diabetes being associated with 
altered lipid metabolism, is commonly accompanied 
by thyroid dysfunction. This can produce significant 
metabolic disturbances that share in the mechanisms 
of DCM [7].  
Accordingly in DM, hyperglycemia, disturbed 
thyroid functions and altered lipid metabolism may 
have a great role in the development of DCM and the 
correction of such disturbances will be very helpful in 
preventing its development. So, it is of extreme 
importance to evaluate the efficacy of management of 
DM in the correction of these changes and in 
prevention of DCM development and other 
cardiovascular complications. 
The aim of the present work was to study the 
effect of induction of both types of DM on lipid profile 
and thyroid hormones plasma levels and the role of 
these metabolic disturbances in the development of 
DCM. Also, we investigated the role of treatment with 
insulin and rosiglitazone (used for treatment of type 1 
and 2 DM respectively) in the control of these 
changes and in improvement of myocardial 
dysfunction in diabetic rats. 
 
Material and Methods 
Animals 
Fifty adult male Wistar albino rats weighed 
between 200 – 250 g were housed in wire mesh 
cages at room temperature. Veterinary care was 
provided by local laboratory animal house unit in 
Faculty of Medicine, Cairo University. All animals were 
handled according to the guidelines established by 
institutional animal care and use committees. Rats 
were housed with normal light dark cycle, and were 
allowed to acclimatize to their environment for five 
days before start of experiment. All animals were kept 
under the same environmental conditions and had 
free access to water and food. The rats were divided 
into five groups (each group consisted of 10 rats) as 
follows; group I (control group), group II (Type 1 
diabetic rats), group III (Type 2 diabetic rats), group IV 
(Insulin treated type 1 diabetic rats) and group V 
(rosiglitazone treated type 2 diabetic rats). 
Induction of experimental type 1 diabetes: 
Thirty rats were injected intraperitoneally (i.p.) with a 
single dose  of  60 mg/kg  of streptozotocin (STZ) 
(Sigma, Chemical Co., St. Louis, MO, USA) dissolved 
in sodium citrate buffer (0.1 mol/liter, pH adjusted to 
4.5) at a concentration of 20 mg/ml immediately 
before use [8]. After 3 days, fasting blood samples 
were collected through the retro-orbital route using 
capillary tubes to assess glucose level by using a 
glucometer (Aquo-Check, Roche). Animals showing 
blood glucose higher than 200 mg/dl were considered 
as diabetic and twenty of them were used for the 
study [9]. 
Induction of experimental type 2 diabetes: 
High–fructose diets (HFD) are usually used to induce 
type 2 diabetes animal model [10]. Thirty rats were fed 
with high fructose diet (60% fructose) and water for 4 
weeks after which fasting blood samples were 
withdrawn through the retro-orbital route using 
capillary tubes to assess glucose level. Rats exhibiting 
plasma glucose more than 200 mg/dl were considered 
to have type 2 diabetes [9] and twenty of them were 
used for the study. The animals were kept on the HFD 
throughout the whole period of the study (for 
additional four weeks after development of diabetes). 
 
Insulin treatment protocols 
Four weeks after streptozotocin injection, 
diabetic animals were placed on an insulin regimen for 
four weeks. For these animals, insulin doses were 
individually adjusted to maintain the euglycemia state. 
Insulin was given in a dose of 10 IU/kg/day 
subcutaneously once per day between 9:00 and 11:00 
a.m. Diabetic animals whose body weight fell below 
90% of initial starting body weight during the in vivo 
protocol had to be eliminated from the study [11]. 
However, no animals were eliminated as there was no 
reduction in their body weight below 90% of the 
original weight. 
 
Administration of rosiglitazone 
Rosiglitazone maleate is an oral antidiabetic 
agent which acts primarily by increasing insulin 
sensitivity. After the development of type 2 DM by 
administration of HFD (the time at which 
hyperglycemia was confirmed), rosiglitazone was 
given to the diabetic animals for four weeks. It was 
given orally in a dose of 10 mg/kg/day dissolved in 10 
ml distilled water via intra-gastric tube. This dose was 
chosen because it has been shown to be the effective 
therapeutic dose in diabetic rats [12].  
 
Samples Used 
Blood samples were withdrawn from all rats 
through the retro-orbital route using heparinized 
capillary tubes. The blood samples were delivered into 
centrifuge tubes then, centrifuged at 10,000 rpm for 
20 minutes and plasma was separated and stored at  
-70˚C until used. The plasma was divided into 3 tubes 
for further determination of plasma levels of glucose, 
T3, T4, triglycerides (TG) and total cholesterol (TC). 
 
Heart perfusion Conditions 
After taking blood samples, all animals were 
heparinized with 100 U of heparin intraperitoneally 
(i.p.) for 15 min. Animals were then anesthetized with 
10 mg/Kg sodium pentobarbitone (i.p.). The hearts 
were excised and placed in ice – cold Krebs – 
Henseleit Bicarbonate (KHB) buffer. Extraneous 
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tissues (Pericardium, lung, trachea, etc.) were 
removed. Aorta was cannulated with an 18 – gauge 
plastic cannula, in a non circulating Langendorff 
apparatus, with modified Krebs Henseleit solution at a 
constant flow rate of 12 ml/min. The perfusate solution 
consists of the following (in mmol/l): NaCl (116), 
NaHCO3 (25), CaCl2 (205), MgSO4 (102), KCl (407), K 
H2PO4 (102) and glucose (5.5). The Langendorff 
apparatus was water jacketed to maintain a core 
temperature of the heart 38°C. The perfusate was 
oxygenated with 95% O2 and 5% CO2 gas mixture to 
maintain a PO2 of > 40 mmHg. A water–filled latex 
ballon–tipped catheter was inserted into the left 
ventricle through the mitral annulus and inflated with 
distilled water (0.15 – 0.3 ml) to set an end diastolic 
pressure of 2 mmHg during the initial equilibration. 
The distal end of the catheter was connected to a 
polygraph (san–ei Japan) for recording the different 
haemodynamic parameters, via pressure transducer, 
according to the experimental design. Contractile 
function was assessed by measuring the following 
parameters: Heart rate (HR), left ventricular 
developed pressure (LVDP) which is defined as peak 
systolic minus end-diastolic pressure and the 
maximum rate of pressure rise (+dp/dt). 
 
Pharmacological drugs used 
Rosiglitazone was obtained from Smith Kline 
Beecham pharmaceuticals, Philadelphia, PA 19101, 
U.S.A. Long acting protamine zinc insulin (PZI) was 
purchased from Nile Company (Egypt). Fructose was 
obtained from Sigma-Aldrich Labrorchemik-alien 
GmbH. D-30976 Seelze. 
 
Biochemical estimation 
The blood glucose was assayed by the 
method adopted by Trinder [13] using kits supplied by 
Diamond Diagnostics. Fasting plasma TG was 
assayed by the method previously adopted by 
Wahlefeld [14] using TG quantification kit supplied by 
BioVision Research. Fasting plasma cholesterol was 
assayed by the method previously described by 
Sundvall et al. [15] using cholesterol assay kit 
supplied by  BioAssay Systems. Plasma total T3 and 
T4 concentrations were determined by 
radioimmunoassay methods adopted by Burtis and  
Ashwood [16] using reagent kits purchased from 
Diagnostic Systems Laboratories (USA). 
 
Statistical Methods 
Data were processed using the Statistical 
Package for Social Sciences® (SPSS) program v. 20 
(Chicago, IL, USA). Descriptive statistics were used, 
as means (M) and standard deviations (SD), 
frequency distribution, and comparisons. One way 
ANOVA test was used to compare between groups, 
followed by post hoc test (least significant difference) 
for inter-group comparisons. We considered 
differences to be statistically significant if P values 
were < 0.05. 
 
Results 
1. Effect of induction of diabetes and its 
treatment with insulin and rosiglitazone on 
blood glucose, plasma triglycerides and total 
cholesterol levels in type 1 and type 2 
diabetes respectively (Table 1). 
In group II, the induction of type 1 diabetes 
resulted in significant increase in blood glucose, 
plasma TG and TC as compared with group I. 
Similarly, the same changes are observed in group III 
(type 2 DM). However, blood glucose and plasma TC 
was significantly lower, and TG was significantly 
higher in group III than group II. Treatment of type I 
diabetic rats with insulin in group III caused significant 
reduction of blood glucose, plasma TG and TC levels. 
Also, treatment of type 2 diabetic rats with 
rosiglitazone in group V produced significant decrease 
in these parameters. Also, in rosiglitazone treated 
type 2 diabetic rats (group V) TG was significantly 
lower compared to insulin treated type1 diabetic rats 
(group IV). On the other hand, the reverse occurred 
for plasma TC level as it was significantly higher in 
group V compared to group IV. 
 
Table 1: Effect of induction of diabetes mellitus and its treatment with insulin and rosiglitazone on blood glucose, plasma 
triglycerides and total cholesterol levels in type 1 and type 2 diabetes respectively. 
 ControlGroup (G1) Type 1 diabetic rats (G2) Type 2 diabeticrat (G3) 
Type 1 DM with 
insulin(G4) 
Type 2 DM with 
rosiglitazone (G5) 
Glucose (mg/dl) 95.8 ± 14.34 388.7 ± 36.90* 232.60 ± 37.85 # 117.60 ± 29.91
†
 101.20 ± 10.76 
◊
 
Triglycerides (mg/dl) 66.1 ± 11.14 140.5 ± 9.58 * 192.3 ± 18.05 # 103.1 ± 2.28 
†
 75.6 ± 7.52 
◊
 
Total cholesterol (mg/dl) 83.5 ± 7.81 223.3 ± 11.91* 144.3 ± 6.45 # 96.7 ± 6.4 
†
 114.6 ± 4.67 
◊
 
Data are expressed as mean ± SD.  * p < 0.05 group 2 compared with the group 1. # p < 0.05 group 3 compared with the group 1. 
† 
p < 0.05 group 4 compared with the group 2. 
◊ 
p < 0.05 group 5 compared with the group 3. 
 
2. Effect of induction of diabetes and its 
treatment with insulin and rosiglitazone on 
plasma tri-iodothyronine (T3) and tetra-
iodothyronine (T4) levels in type 1 and type 2 
diabetes respectively (Table 2) 
The induction of type 1 and type 2 diabetes in 
group II and III respectively produced significant 
decrease in both T3 and T4 plasma levels. However, 
this reduction is more evident in group II than group 
III. Treatment of type 1 diabetic rats with insulin (group 
IV) and type 2 diabetic rats with rosiglitazone (group 
V) resulted in significant increase in plasma levels of 
both hormones indicating improvement in thyroid 
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functions. Also, plasma T3 was significantly lower 
while, plasma T4 was significantly higher in 
rosiglitazone treated type 2  diabetic rats (group V), 
compared to insulin treated type 1 diabetic rats (group 
IV). 
 
 
Table 2: Effect of induction of diabetes mellitus and its treatment with insulin and rosiglitazone on plasma tri-iodothyronine (T3) 
and tetra-iodothyronine (T4) levels in type 1 and type 2 diabetes respectively. 
 Control Group (G1) Type 1 diabetic rats (G2)  
Type 2 diabetic rat (G3) 
 
Type 1 DM with insulin 
(G4)  
Type 2 DM with 
rosiglitazone (G5) 
T3 (ng/dl) 285.90 ± 12.37 134.50 ± 11.33 * 189.70 ± 11.50 # 256.60 ± 17.75 
†
 222 ± 5.68 
◊
 
T4(ug/dl) 7.52 ± 0.80 2.19 ± 0.36 * 4.98 ± 0.21 # 5.09 ± 0.57 † 6.58 ± 0.47 ◊ 
Data are expressed as mean ± SD. *p < 0.05 group 2 compared with the group 1. #p < 0.05 group 3 compared with the group 1. 
† 
p < 0.05 group 4 compared with the group 2. 
◊ 
p < 0.05    
group 5 compared with the group 3. 
 
3. Effect of induction of diabetes and its 
treatment with insulin and rosiglitazone on 
heart rate, left ventricular developed pressure 
(LVDP) and maximum rate of pressure rise 
(+dp/dt) in type 1 and type 2 diabetes 
respectively (Table 3) 
In groups II and III, the induction of type 1 and 
type 2 diabetes by streptozotocin and HFD 
respectively resulted in significant reduction in heart 
rate, left ventricular developed pressure (LVDP) and 
+dp/dt. Also, LVDP increased significantly in group III 
compared to group II, while regarding HR and +dp/dt 
there is no significant differences between the 2 
groups. The treatment of group IV with insulin and 
group V with rosiglitazone produced significant 
elevation in the same parameters. However, all these 
parameters were significantly lower in rosiglitazone 
treated group V diabetic rats compared to insulin 
treated group IV diabetic rats. 
 
Table 3 : Effect of induction of diabetes mellitus and its treatment with insulin and rosiglitazone on heart rate, left ventricular 
developed pressure (LVDP) and maximum rate of pressure rise (+dp/dt) in type 1 and type 2 diabetes respectively. 
 Control Group (G1) 
Type 1 diabetic rats (G2) 
 
Type 2 diabetic rat (G3) 
 
Type 1 DM with insulin 
(G4) 
Type 2 DM with 
rosiglitazone (G5) 
Heart rate (beat/min) 178.60 ± 3.63 92.50 ± 6.88 * 99.40 ± 7.23 #    153.30 ± 10.13 
†
 104.70 ± 6.075 
◊
 
LVDP (mmHg) 100 ± 2.67 23.30 ± 2.98 * 50.90 ± 3.73 #    88.80 ± 2.86 
†
 69.10 ± 1.20 
◊
 
+dp/dt (mmHg/sec) 69.30 ± 2.66 38.70 ± 2.11 * 39.50 ± 2.46 #    61.40 ± 3.10 
†
 49.80 ± 2.10 
◊
 
Data are expressed as mean ± SD. *p < 0.05 group 2 compared with the group 1. #p < 0.05 group 3 compared with the group 1. 
† 
p < 0.05 group 4 compared with the group 2. 
◊ 
p < 0.05    
group 5 compared with the group 3. 
 
 
Discussion 
Diabetic cardiomyopathy (DCM) is a clinical 
condition diagnosed when ventricular dysfunction 
develops in patients with diabetes in the absence of 
coronary atherosclerosis and hypertension [17]. It was 
pointed out that diabetes associated with altered lipid 
metabolism is commonly accompanied by thyroid 
dysfunction. This can produce significant metabolic 
disturbances that share in the mechanisms of DCM 
[7]. 
In our study, the untreated diabetic rats (both 
type 1 & 2) exhibited an altered lipid metabolism 
manifested by significant increase in plasma level of 
TG and TC. These changes were in accordance with 
the work of Dansky et al. who found that both STZ-
induced and fructose-induced diabetic rats developed 
elevations of TG and TC levels [18]. Several factors 
are likely to be responsible for this diabetic 
dyslipidemia. As insulin has a profound role in the 
regulation of key enzymes involved in the lipid and 
lipoprotein metabolism and due to its role on the 
synthesis and expression of apolipoproteins in hepatic 
and extra hepatic tissues, its deficiency or defect in its 
function affects overall lipid metabolism and lipid 
profile of various tissues [19]. In addition, a previous 
study showed that, cholesterol absorption is increased 
in insulin dependent diabetes and can be corrected by 
insulin treatment [20]. 
Interestingly, we observed in this work that 
DM especially type 2 showed more 
hypertriglyceridemia than type 1. This is because of 
peripheral insulin resistance and increased flux of fatty 
acids to the liver in type 2 DM. Also, there may be a 
reduction in total lipoprotein lipase activity or 
increased concentrations of the lipoprotein lipase 
inhibiting proteins [21]. 
Our results also demonstrated a highly 
significant reduction in plasma level of T3 and T4 in 
groups II, III respectively relative to control group. This 
effect of diabetes appears to involve changes in 
hypothalamic thyrotropin-releasing hormone (TRH) 
secretion and pituitary thyrotropin (TSH) release [22]. 
More importantly, this reduction is more evident in 
type 1 than type 2 as we noticed a higher T3 and T4 
in type 2 diabetics (group III) relative to type 1 
diabetics (group II). These results were in harmony 
with the results of another study which reported the 
same findings [23].  
Data of the present work demonstrated that 
relative to control group I, cardiac mechanical 
performance was significantly reduced in type 1 and 
type 2 diabetic hearts (groups II & III respectively). A 
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highly significant decrease in HR, LVDP and +dp/dt 
was recorded in both groups signifying that isolated 
hearts from diabetic rats exhibited a certain degree of 
DCM. Our results are in agreement with the work of 
other researchers who reported similar findings in 
diabetic rats [24,25]. Indeed, alterations of diastolic 
and systolic function are widely reported in 
uncomplicated diabetic subjects and often predict the 
development of other chronic diabetic complications 
[26]. 
Although the etiology of myocardial injury and 
dysfunction in diabetes is not well understood, 
alteration of energy substrates in the form of excess 
plasma glucose and lipids can directly or indirectly 
induce mitochondrial reactive oxygen species (ROS) 
formation in the myocardium. DCM begins with a 
disturbance in the glucose metabolism that provokes 
hyperglycemia. A feature common to all cell types that 
are damaged by hyperglycemia is an increased 
production of advanced glycation end products 
(AGEs) and ROS [27,28]. High concentration of 
glucose triggers AGEs synthesis, in particular, 
glycated extra matrix proteins such as collagens. 
AGEs bind its specific receptors (RAGE) to activate 
NADPH oxidase (NOX) and to release ROS [29]. 
Protein kinase C (PKC) can also be stimulated by 
AGEs to phosphorylate proteins involved in 
Ca
2+
 handling and cardiomyocyte contraction [30, 31]. 
In addition, acute exposure to high glucose elevates 
inducible nitric oxide synthase (iNOS gene) 
expression and subsequent nitric oxide (NO), and 
peroxynitrite (ONOO−), which in turn stimulate poly-
ADP ribose-polymerase-1 enzyme (PARP) as a 
compensatory antioxidant mechanism [32]. Increased 
accumulation of fatty acids (FAs) and their derivatives 
fatty acyl CoA, diacyglycerol (DAG), and ceramide 
dampens insulin signaling through activation of serine 
kinases such as protein kinase C [33]. Another target 
of free FAs in cardiomyocytes is the peroxisome 
proliferator-activated receptors-alpha (PPAR-α) 
pathway. An increase in PPAR-α expression was 
reported in almost all rodent models of DCM [34]. 
The dramatic accumulation of intramyocardial 
lipids in the diabetic heart led to the hypothesis of 
“toxic lipids” as mediators of cardiac dysfunction in 
DCM [35]. Accumulation of ceramide and 
diacylgycerol (DAG) has been demonstrated to alter 
intracellular signaling pathways and promote apoptotic 
cell death [36]. On sympathetic activation, augmented 
accumulation of norepinephrine, increased oxidative 
stress, and apoptosis may have contributed to 
abnormal vascular reactivity [37]. 
Moreover, the pathogenesis of myocardial 
dysfunction in diabetes can be explained by defects in 
calcium signaling. It was reported that the reduced L-
type Ca²+ current density in myocytes from diabetic 
mice is partly due to reduced cell surface expression 
of the L-type Ca²+ channel [38]. The release of 
calcium ions from internal sarcoplasmic reticulum via 
type 2 ryanodine receptor calcium–release channel is 
an integral step in the cascade of events leading to 
cardiac muscle contraction [39]. Other potential 
mechanism is that the decrease in LVDP might be 
due to increased collagen deposition or increased 
glucose–mediated collagen cross–linking in diabetic 
mice independent of myocyte pathology [40]. 
The decreased myocardial performance 
observed in our study can be explained by significant 
decrease in the levels of T3 and T4 as observed in 
both type 1 and type 2 diabetic rats [41]. As diabetic 
animals had decreased values of circulating thyroid 
hormones and similar diminished thyroid hormone 
levels have been observed in humans with diabetes. 
The observed Hypothyroidism could induce cardiac 
remodeling in 3 ways; Firstly, by decreasing the 
activity of some enzymes included in intracellular 
calcium handling which further changes the 
expression of contractile protein [42]. Secondly, 
chronic inflammation [43] and tissue changes such as 
collagen alteration, dehydration or capillary 
distribution [44]. Thirdly, subclinical hypothyroidism is 
associated with hemodynamic changes that could 
also induce cardiac impairment [45]. In addition to the 
above-mentioned mechanisms that could induce LV 
dysfunction, increased systemic vascular resistance 
[46] and activation of the sympathetic nervous system 
and the renin-angiotensin-aldosterone system could 
also have a significant role in hemodynamic and 
structural changes of the LV [47]. 
In an attempt to assess the role of the 
different altered metabolic parameters on myocardial 
function, we compared the cardiac mechanical 
efficiency in both type 1 and type 2 diabetic rats. We 
found that LVDP in type 2 was significantly higher 
than in type 1 diabetic rats, while there was no 
significant difference in heart rate and +dp/dt. In 
support of our study, a previous research 
demonstrated that impaired LVDP and mechanical 
efficiency are maintained in type 2 more than type 1 
diabetic mice [48]. 
Compared to non treated type 1 diabetic rats, 
treatment with insulin in group IV produced a highly 
significant decrease of blood glucose level and this 
improvement reached nearly normal level as no 
significant difference was observed relative to control 
group. Concerning the thyroid hormones, T3 and T4 
levels were significantly increased in treated group IV 
as compared to non treated group II. While relative to 
control group, T3 and T4 levels were still significantly 
low. Improvement of thyroid hormones levels as 
observed in insulin treated type 1 diabetic rats was in 
agreement with Kosova et al. who noticed that there 
was a significant decrease in serum level of thyroid 
hormones in type 1 STZ induced diabetic rats and this 
decrease was greatly corrected after prompt 
subcutaneous insulin therapy [49]. One of the 
contributing factors involved in the hypothyroid state 
observed in diabetics are the changes that occur in 
hypothalamic TRH secretion as well as changes in 
pituitary thyrotropin hormone release. Insulin therapy 
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can normalize the hypothalamo-pituitary-thyroid axis, 
and increase the iodide trapping to thyroid gland in 
diabetic models [50]. 
Regarding mechanical cardiac performance, 
we found that insulin treatment of type 1 diabetic rats 
(group IV) resulted in a highly significant improvement 
of HR, LVDP, and +dp/dt compared to non treated 
type 1 diabetic rat (group II). However, relative to 
control group a significant difference still existed. 
These data suggest that type 1 diabetes results in 
progressive marked changes in the myocardium that 
can be prevented or improved by early insulin 
treatment. These results are consistent with the 
results of several authors who proved that insulin 
therapy for type 1 diabetic rats can improve the 
mechanical parameters of the heart and the metabolic 
dysfunction accompanying diabetes [3,51,52]. Several 
studies explained the protective effect of insulin on the 
heart as follows: the decrease in cardiac contractility 
induced by chronic diabetes results in part from 
decrease in expression and alteration in function of 
rayanodine type 2 calcium release channel in cardiac 
myocyte and these changes can be reversed by 
insulin treatment [53]. 
Although insulin increases transport of 
glucose into the cardiac myocytes, it has been 
demonstrated that insulin promotes a positive 
inotropic effect independent of glucose uptake [54]. 
Increasing evidence indicates that, in addition to its 
inimitable function in glucose metabolism, insulin 
plays critical roles in a variety of other physiological 
and pathological modulations, such as regulation of 
inflammatory response and nitric oxide production 
[55]. The improvement of cardiac power and 
metabolic parameters by insulin is due to 
overexpression of glucose transporter 4 (GLUT-4) 
[56]. In addition, in the mice insulin therapy has been 
found to increase T cell production of interleukin-4 (IL 
– 4), a cytokine associated with protection against 
diabetic ischemic heart [57]. Inukai reported that 
insulin affects the activity of genes that have insulin-
responsive regions in their promoters in heart [58]. 
The discovered Insulin-Induced genes (Insig) may be 
responsible for other insulin mediated cardiac effects 
[59]. Furthermore, increased norepinephrine content 
in diabetic myocardium was completely prevented by 
insulin therapy started immediately after 
streptozotocin injection [60]. The altered pattern of 
substrate metabolism was restored to normal in 
perfused hearts from insulin treated rats, and 
contractile function was normalized even though signs 
of diabetes (hyperglycemia and hyperlipidemia) were 
still evident, indicating that altered cardiac metabolism 
is an important causative factor in the contractile 
dysfunction [61]. 
Concerning rosiglitazone treatment of type 2 
diabetes (group V) for one month, we found that this 
drug produced highly significant decrease in blood 
glucose compared to non treated rats and with no 
significant difference relative to control rats. 
Rosiglitazone also produced highly significant 
decrease of plasma TG and TC levels as compared to 
non treated type 2 diabetic rats but still significantly 
lower than the normal rats. Rosiglitazone also affected 
the plasma  levels of T3 and T4 as we noticed a 
significant increase in their levels, but this 
improvement was still significantly lower than the 
normal control levels. 
Our results demonstrated that rosiglitazone 
improves the insulin sensitivity as it lowers the blood 
glucose level. Also, it improves the plasma level of TG 
more than TC level and elevates T3 and T4 levels as 
compared to untreated type 2 diabetic rats. Serum 
metabolic and lipoprotein subclass changes, which 
may be associated with this rosiglitazone-induced 
improvement may occur through the binding of 
rosiglitazone to peroxisome proliferator activated 
receptor gamma (PPARγ)  resulting in improved 
insulin sensitivity and redistribution of adipose tissue. 
Also, it was reported that rosiglitazone not 
only improved the insulin action, but also improved β – 
cells function [62]. Moreover, it decreased circulating 
TG, FFA and TC levels in rats without altering the total 
weight of white adipose tissue [63]. In addition, 
rosiglitazone might have an enhanced rate of TG 
removal by reducing insulin resistance in peripheral 
tissues and increasing the action of insulin on 
lipoprotein lipase (LPL) [64]. Our results also revealed 
a rising effect of rosiglitazone on thyroid hormones. 
This may be due to the direct effect of rosiglitazone on 
the thyroid gland through increasing its iodide trapping 
and binding and enhancing all the process of thyroid 
hormones synthesis [65]. 
Also, this explanation was confirmed by the 
Western blot studies with the sodium iodide symporter 
(NIS) which showed that rosiglitazone effect on iodide 
transport is expressed, at least in part, by an 
increased thyroid tissue content of the NIS transporter 
[66]. Our results are in agreement with other 
researchers work who demonstrated that rosiglitazone 
has an improving effect on cardiac performance 
[56,67]. Also, the protective effect of rosiglitazone 
against myocardial diabetic injury was evident by 
attenuation of decrease in +dp/dt and LVDP rats [68]. 
Moreover, rosiglitazone  produced cardiac protection 
due to increase in angiotensin II (AT2) receptor mRNA 
and a marked reduction in angiotensin I (AT1) 
receptor mRNA. The mechanisms of AT2 receptor-
mediated cardioprotection, involve stimulation of 
protein tyrosine or serine/threonine phosphatases in a 
Gi protein-dependent manner [69]. 
Conclusion: We concluded that the induction 
of both types of diabetes resulted in decreased 
myocardial performance parameters. The treatment of 
type 1 and type 2 DM by insulin and oral rosiglitazone 
respectively improved to a great extent the metabolic 
disturbances and  myocardial contractile function with 
more improving effect of  insulin in type 1 than 
rosiglitazone in type 2 DM. So, treatment of DM is 
Alsawy & El-Damarawi. Diabetes Mellitus and Its Control on Myocardial Contractile Function in Rats 
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very important for improvement of myocardial 
dysfunction and management of DCM. 
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